HK Stock Market Move | RIBOLIFE-B(06938) early trading rose more than 7%, Vortosiran atrial fibrillation stroke prevention Phase IIb application successfully submitted.

RIBOLIFE-B (06938) rose over 7% in early trading, up 6.04% at the time of publication to HKD 72.9, with a trading volume of HKD 11.7261 million. In terms of news, Ribolife announced that its core product Vortosiran (RBD4059) has successfully submitted a Phase 2b clinical trial application (CTA) for stroke prevention in atrial fibrillation (SPAF) patients to the European Medicines Agency (EMA). This is the world's first small interfering nucleic acid (siRNA) Factor XI (FXI) inhibitor in atrial fibrillation (AF) clinical trials, marking an important milestone in the clinical development of siRNA drugs in anticoagulation therapy. Ribolife plans to conduct Phase IIb clinical trials covering a variety of thrombotic and cardiovascular indications, including the clinical trial codenamed ORBIT-XI-AF submitted this time. With the completion of the Phase IIa trial of Vortosiran for coronary artery disease (CAD), this submission will further consolidate and strengthen the product's leading position as the world's fastest FXI-targeting small nucleic acid drug.